Amgen Wins Ban On Teva's Generic Version Of Sensipar

Law360, New York (January 7, 2011, 7:44 PM EST) -- A federal judge on Friday barred Teva Pharmaceutical Industries Ltd. and its subsidiary Barr Laboratories Inc. from selling a generic version of Amgen Inc.'s kidney drug Sensipar until the patents covering it expire in 2018.

Judge Harvey Bartle III of the U.S. District Court for the District of Delaware rejected Teva's argument that the three patents at issue were invalid due to inequitable conduct and entered an injunction blocking the generics maker from making or selling its planned version of Sensipar.

Sensipar had worldwide sales of...
To view the full article, register now.